Literature DB >> 1437502

Dealing with sadness, madness and hostility. New psychotropic drug remedies for the future.

A J Loonen1.   

Abstract

The objective of this article is to present an overview of new forms of psychotropic drug therapy that may be expected to play a role in psychiatric practice in the 1990s. In predicting these future developments, three lines of approach have been followed. Firstly, progress in elucidating basic neuronal mechanisms is described. The radioligand receptor binding technique has proved to be an especially powerful tool in the search for novel psychoactive compounds. Secondly, those mental health problems most likely to undergo intensive study are discussed. It is likely that special attention will be devoted to organic mental disorders related to aging (dementia) or chronic exposure to toxic substances. In addition, research will be aimed at explaining and reducing the occurrence of auto-aggressive and hetero-aggressive behaviour. Thirdly, the types of newly designed agents and treatment strategies currently under investigation are outlined. In particular, the development of pharmacological agents that interfere with serotonergic molecular mechanisms has opened the way to improving existing psychotropic drugs, to inventing drugs that achieve known clinical effects via different mechanisms of action, and even to discovering entirely new categories of psychotropic drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1437502     DOI: 10.1007/bf01962542

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  125 in total

Review 1.  The molecular biology of serotonin receptors. An overview.

Authors:  P Hartig; H T Kao; M Macchi; N Adham; J Zgombick; R Weinshank; T Branchek
Journal:  Neuropsychopharmacology       Date:  1990 Oct-Dec       Impact factor: 7.853

Review 2.  Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors.

Authors:  E S Deneris; J Connolly; S W Rogers; R Duvoisin
Journal:  Trends Pharmacol Sci       Date:  1991-01       Impact factor: 14.819

3.  Isolation, primary structure, and synthesis of alpha-endorphin and gamma-endorphin, two peptides of hypothalamic-hypophysial origin with morphinomimetic activity.

Authors:  N Ling; R Burgus; R Guillemin
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

Review 4.  Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia.

Authors:  A Y Deutch; B Moghaddam; R B Innis; J H Krystal; G K Aghajanian; B S Bunney; D S Charney
Journal:  Schizophr Res       Date:  1991 Mar-Apr       Impact factor: 4.939

5.  How selective is GR 43175? Interactions with functional 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors.

Authors:  P Schoeffter; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

6.  Suicide and the attempted suicide: an international perspective.

Authors:  R F Diekstra
Journal:  Acta Psychiatr Scand Suppl       Date:  1989

Review 7.  The use of anticonvulsants in manic-depressive illness.

Authors:  J C Ballenger
Journal:  J Clin Psychiatry       Date:  1988-11       Impact factor: 4.384

8.  Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients.

Authors:  M Ansseau; R von Frenckell; C Mertens; J de Wilde; L Botte; J M Devoitille; J L Evrard; A De Nayer; P Darimont; G Dejaiffe
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 9.  Propranolol in psychiatry. Therapeutic uses and side effects.

Authors:  J Ananth; K M Lin
Journal:  Neuropsychobiology       Date:  1986       Impact factor: 2.328

10.  Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A negative, double-blind, placebo-controlled trial.

Authors:  A J Loonen; H A Verwey; P R Roels; L P van Bavel; C H Doorschot
Journal:  J Clin Psychopharmacol       Date:  1992-02       Impact factor: 3.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.